FYERS
Home
/
Stocks
/
Results
/
Supha Pharmachem Results

Supha Pharmachem Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
---0%
---0%
--33%-84%-78%
5%5%5%5%

Peer Comparison

Symbol
ADANIENT-A
PREMIERENE-A
AEGISLOG-A
CPPLUS-A
REDINGTON-A
HONASA-A
LLOYDSENT-A
CELLO-A
JSLL-A
BLACKROSE-T
SUPHA-Z
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
2,931.25₹390684 Cr52.48-8.91105.06₹9339 Cr
1,002.35₹45486 Cr27.3210.245.28₹1510 Cr
1,277.2₹45144 Cr36.0813.841.65₹898 Cr
3,760₹44346 Cr92.9112.0745.29₹368 Cr
368.9₹29113 Cr17.126.2224.36₹1490 Cr
480.75₹15566 Cr62.552.778.99₹200 Cr
73.17₹10984 Cr97.810.380.91₹283 Cr
343.6₹7747 Cr24.773.3217.46₹332 Cr
509₹6238 Cr26.375.2923.32₹222 Cr
113₹572 Cr19.992.046.4₹22 Cr
0.27₹25 Cr11.60.10.02₹2 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Sep 2025Jun 2025Mar 2025
₹111 Cr₹113 Cr₹264 Cr
₹3 Cr₹3 Cr₹66 L
₹114 Cr₹117 Cr₹265 Cr
₹104 Cr₹111 Cr₹265 Cr
₹11 Cr₹5 Cr₹20 L
₹19 L-₹37 L₹2 Cr
₹10 Cr₹6 Cr-₹1 Cr
₹9 Cr₹5 Cr-₹2 Cr

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Deferred Tax Assets / Liabilities
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2025
—
₹40 Cr
₹4 Cr
₹4 Cr
₹44 Cr
-₹4 L
-₹4 L
—
₹501 Cr
₹32 Cr
₹1141 Cr
₹2 Cr
₹1676 Cr
₹1720 Cr
₹1141 Cr
—
₹22 L
₹22 L
₹83,000
₹83,000
—
₹269 Cr
₹772 Cr
₹1 Cr
₹3 Cr
₹675 Cr
₹1720 Cr
₹44 Cr
₹1720 Cr
₹1
₹1

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Closing Cash & Cash Equivalent
Mar 2025
₹4 Cr
₹5 Cr
-₹1144 Cr
-₹1135 Cr
-₹1135 Cr
₹13 L
₹1136 Cr
₹1 Cr
₹1 Cr

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)0.28
Volume (₹)18.65 L
High (₹)0.28
Upper Circuit0.29
Low (₹)0.27
Lower Circuit0.27
Prev Close0.28
52W High (₹)1.80
Price0.27
52W Low (₹)0.25

Share Market Cap & Key Ratios Overview

M.Cap (₹)24.70 Cr
Div. Yield (%)0.00
PE Ratio11.60
Debt to Equity26.01
Price to Book1.67
Book Value0.76
EPS (TTM)0.02
Face Value1.00
ROE (%)4.85

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
ADANIENT-ANSE
PREMIERENE-ANSE
AEGISLOG-ANSE
CPPLUS-ANSE
REDINGTON-ANSE
HONASA-ANSE
LLOYDSENT-ANSE
CELLO-ANSE
JSLL-ANSE
BLACKROSE-TNSE
SUPHA-ZNSE
LTP
1W Low
1W High
Market cap (₹)
2931.25-234.75 (-7.41%)
2831.65
3168
3,90,684Cr
1002.35-11.65 (-1.15%)
995.50
1028.55
45,486Cr
1277.2-12.4 (-0.96%)
1180.45
1327.30
45,144Cr
3760+183.05 (5.12%)
3458.85
3796.35
44,346Cr
368.9+3.05 (0.83%)
343.80
378.95
29,113Cr
480.75+10 (2.12%)
465.25
494
15,566Cr
73.17+0.03 (0.04%)
69.53
74.50
10,984Cr
343.6-7.4 (-2.11%)
340.85
357.45
7,747Cr
509-2.95 (-0.58%)
497.75
529.70
6,238Cr
113-2 (-1.74%)
110.60
116.95
572Cr
0.27-0.03 (-10.00%)
0.27
0.30
25Cr

Supha Pharmachem Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹10.62Cr; with other income of ₹3.25Cr, profit before interest and tax came to ₹10.62Cr. Interest expense was ₹18.7Lakh; PBT before exceptional items stood at ₹10.44Cr. Cost mix (full year): raw materials ₹534.28Cr; employee cost ₹40.97Lakh; depreciation ₹0 cr; other expenses ₹103.69Cr. Basis: consolidated annual results.

Supha Pharmachem Ltd Quaterly Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹10.62Cr; with other income of ₹3.25Cr, profit before interest and tax came to ₹10.62Cr. Interest expense was ₹18.7Lakh, taking profit before tax to ₹10.44Cr.